This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Over the last 20 years, Cisbio has become a leading Life Sciences company which develops, manufactures, and markets high quality kits and reagents for the drug discovery and life science markets used by pharmaceutical, biotechnology, academia and contract research organizations across the globe. Learn more about Cisbio here.
BW2014 has been heavily cited in the drug discovery literature (it was cited as the first reference in the ACS assay interference editorial which I reviewed in K2017 ) despite providing nothing in the way of practical advice for dealing with nuisance behavior. Given that M2003 had been published over a decade previously.
Drug discovery is always evolving. From new processes to advanced technologies, excellence in drug discovery is the result of combining different approaches. Emerging and Resurrecting Technologies We’ve made huge strides in the drug discovery process, and it’s only getting better as we move forward.
In this blog, we highlight some of the solutions available for researchers to tackle atherosclerotic vascular disease: from fundamental research rooted in ischemia-reperfusion studies and cell-basedassays to drug discovery efforts and the early detection of drug-related side effects.
COVID-19’s Main Viral Protease Identified as Target More Than 10,000 Compounds Quickly Assayed Using computer-aided drug design, the Shanghai-based team identified an inhibitor of M pro , called N3. They then visualized not only the crystal structure of the SARS-CoV-2 virus, but also N3 in complex with SARS-CoV-2.
It’s now time to get back to chemical probes and I’ll be taking a look at S2023 (Systematic literature review reveals suboptimal use of chemical probes in cell-based biomedical research) which has already been reviewed in blog posts from Practical Fragments , In The Pipeline and the Institute of Cancer Research.
ChEMBL contains a broad range of binding, functional and ADMET type assays in formats ranging from in vitro single protein assays to anti proliferative cell-basedassays. Some variation is expected, even for very similar assays, since these are often performed by different groups and institutes.
I’ll start the review of L2021 with annotation of the abstract: "Physicochemical descriptors commonly used to define ‘drug-likeness’ and ligand efficiency measures are assessed for their ability to differentiate marketed drugs from compounds reported to bind to their efficacious target or targets. [I
Since 1962, the FD&C Act has authorized FDA to require that sponsors of clinical trials submit data from “preclinical tests (including tests on animals)” in order to demonstrate that their drug is safe enough to advance to testing in humans. FDORA § 3209(a)(2).
With apologies to Manfred Eigen (1927 - 2019) I've just returned to Cheshire from the Caribbean and, to kick off blogging from 2024 I'll share a photo of the orchids at Berwick-on-Sea on the north coast of Trinidad. Overcoming these challenges will amplify the impact of structural biology on drug discovery.
This guideline, which compliments the ICH Q2 2 Guideline, describes science and risk-based approaches for developing and maintaining analytical procedures suitable for the evaluation of the quality of drug substances and drug products. It is a very useful tool for drug product development.
As is usual for blog posts here at Molecular Design , quoted text is indented with my comments enclosed in square brackets in red italics. There does appear to be some confusion here and it would not generally be valid to valid to assign a ChEMBL arget ID to a cell-basedassay.]
In anti-tumor therapy development, this effect is a main focus of drug discovery. Analysis of cell metabolism in life science research In biology, metabolic readouts can be used as key molecular indicators of healthy cellular functions or as predictors of disease (e.g., These readouts also play a role in drug discovery.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content